Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikulaa Parachuri

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Expert Opinion on Biological Therapy|July 20, 2023
Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South AsiaAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|June 23, 2022
Brolucizumab in polypoidal choroidal vasculopathyAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
American Journal of Ophthalmology|December 14, 2020
Biosimilars for Retinal Diseases: An UpdateAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|February 22, 2022
Retina: a unique subspecialty in the biosimilar landscapeAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|May 13, 2022
The port delivery system with ranibizumab: understanding nuances for clinical use in the real worldAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|June 6, 2019
Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppressionAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|January 12, 2022
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity riskAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
International Journal of Retina and Vitreous|January 31, 2023
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialistsAshish Sharma, Arshad M Khanani, Nikulaa Parachuri, et al.
Eye (London, England)|March 24, 2020
Brolucizumab-key learnings from HAWK and HARRIERAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
American Journal of Ophthalmology Case Reports|March 4, 2022
Ranizurel safety evaluation in real-world -(RaSER) studyAshish Sharma, Jayshree Arunaprakash, Atheeshwar Das, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Expert Opinion on Biological Therapy|July 20, 2023
Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South AsiaAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|June 23, 2022
Brolucizumab in polypoidal choroidal vasculopathyAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
American Journal of Ophthalmology|December 14, 2020
Biosimilars for Retinal Diseases: An UpdateAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Eye (London, England)|February 22, 2022
Retina: a unique subspecialty in the biosimilar landscapeAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|May 13, 2022
The port delivery system with ranibizumab: understanding nuances for clinical use in the real worldAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
Eye (London, England)|June 6, 2019
Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppressionAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
Expert Opinion on Biological Therapy|January 12, 2022
Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity riskAshish Sharma, Nilesh Kumar, Nikulaa Parachuri, et al.
International Journal of Retina and Vitreous|January 31, 2023
Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialistsAshish Sharma, Arshad M Khanani, Nikulaa Parachuri, et al.
Eye (London, England)|March 24, 2020
Brolucizumab-key learnings from HAWK and HARRIERAshish Sharma, Nikulaa Parachuri, Nilesh Kumar, et al.
American Journal of Ophthalmology Case Reports|March 4, 2022
Ranizurel safety evaluation in real-world -(RaSER) studyAshish Sharma, Jayshree Arunaprakash, Atheeshwar Das, et al.
Pageof 7